In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Risky Business – The Future of Biopharmaceutical Innovation

Risky Business – The Future of Biopharmaceutical Innovation

Saturday, June 6, 2020, 9:00 AM - 3:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Catenion

Science Alliance

The New York Academy of Sciences

 

Bio-pharmaceutical companies make some of the biggest and most risky gambles of any industry: each new drug ultimately requires multi-billion-dollar investments. These investments take more than a decade to play out – during which time, profound changes will occur. Internal portfolios wax and wane; competitors’ innovations, regulatory & commercial frameworks reshape the playing field; some therapeutic advancements move the pitch to a new field altogether.

In such an uncertain landscape, companies are constantly rethinking their strategy, and how they can try and take advantage of technical advancements to build innovation models that are fit for the future. With the emergence of open innovation networks, what will be the role for in-house R&D?

Join us again this year to a full-day workshop directed primarily at students and post-docs with an interest in understanding the innovation dynamics of the bio-pharmaceutical industry, and that provides you with a taste of how investment decisions are taken, beating competitors to a lucrative deal, and the challenges the industry faces. Using a competitive board game that has been developed specifically to mimic the pharmaceutical industry, past and present, this workshop will give you the opportunity to take on the role of an executive team of a mid-size company. As a management team, you will develop, execute, alter your strategy in response to your own success and failures, and pounce on the missed opportunities of others. At the end, the winning team will be invited to share their strategy. Major lessons learnt and key questions for the future will be summarized and opened for discussion

Registration

Member
$75
Nonmember Academia, Faculty, etc.
$150
Nonmember Corporate, Other
$250
Nonmember Not for Profit
$150
Nonmember Student, Undergrad, Grad, Fellow
$110
Member Student, Post-Doc, Fellow
$40

Speakers/Facilitators

Matthias Krings, PhD
Matthias Krings, PhD

Catenion

Christoph von Oldenburg
Christoph von Oldenburg

Catenion

Sonia De Munari, PhD
Sonia De Munari, PhD

Catenion

Katarina Ebert
Katarina Ebert

Catenion

Bettina Eyermann
Bettina Eyermann

Catenion

Presenting Partner